Trade AstraZeneca ^AZN

OneAscent Family Office LLC Makes New $613,000 Investment in Astrazeneca Plc $AZN - Stock Observer

Astrazeneca Plc $AZN Shares Purchased by Cibc World Market Inc. - Daily Political

AstraZeneca CEO says AI is reshaping drug development - and helping boost the odds of success

Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 30.8% One-Year Surge?

AstraZeneca (AZN) Stock: Bernstein Identifies 37% Upside Potential in Overlooked Segment

Diamond Blackfan Anemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 - DelveInsight | Novartis AG, AstraZeneca, Pfizer Inc., Sanofi, Merck KGaA

AstraZeneca PLC (AZN) Shares Surge 3.1% -- What GF Score of 83 T

AstraZeneca (AZN) Engages with FDA Leadership on Rare Disease Initiatives

Low-dose Zoladex won't be available in Australia from November. What might that mean for you?

Other news to note for June 4, 2026 | BioWorld

GKV Capital Management Co. Inc. Takes $1.58 Million Position in Astrazeneca Plc $AZN - Daily Political

A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms

Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes

AZN: Recent Drug Approvals And Key Readouts Will Support Bullish Repricing

AstraZeneca CEO: AI is affecting every part of our company

3 UK shares to consider holding in a Stocks and Shares ISA for a decade

SCS Capital Management LLC Reduces Position in Astrazeneca Plc $AZN - Stock Observer

Martin Investment Management LLC Has $54.32 Million Stock Position in Astrazeneca Plc $AZN - Stock Observer

Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions

Norges Bank Makes New Investment in Astrazeneca Plc $AZN - Stock Observer

Northwestern Mutual Wealth Management Co. Has $15.13 Million Stock Position in Astrazeneca Plc $AZN - Stock Observer

AstraZeneca (AZN) Benefits from New FDA Guidance on Gene Therapy Development

AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant

AstraZeneca's (AZN) CARES Phase III Clinical Programme Fails to Meet Primary End Point

ANCA Vasculitis Market to Witness Transformational Growth Opportunities by 2036 - DelveInsight | CSL, Amgen, NS Pharma, Amgen, GlaxoSmithKline, AstraZeneca, Chemocentry, Staidson (Beijing) Biopharma

Regulatory actions for June 2, 2026 | BioWorld

ELRIG unveils keynote speakers for Drug Discovery 2026

Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort

A homoeriodictyol sodium mouthwash reduces bitterness sensitivity in patients with gynecological cancer receiving carboplatin-based chemotherapy

Asthma Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight

AstraZeneca Scores In Liver Cancer On Its Path To $40 Billion In Oncology Sales

AIM ImmunoTech (AIM) Advances Enrollment in Pancreatic Cancer Trial

AstraZeneca (AZN) Reports Positive Results in Phase III Trial for HCC Treatment

Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026 | Morningstar

AstraZeneca's IMFINZI-Based Regimen Cuts Progression Risk By 30% In Liver Cancer Trial

Assessing McCormick (MKC) Valuation After Cindy Hoots Joins The Board Of Directors

Astrazeneca's (AZN) "Buy" Rating Reiterated at Barclays - Daily Political

Regulatory actions for June 1, 2026 | BioWorld

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

Citi Keeps Their Buy Rating on AstraZeneca (AZN)

Legal & General Group Plc Trims Stock Holdings in Astrazeneca Plc $AZN - Daily Political

Cambridge duo Arm and AstraZeneca rewrite corporate history

AstraZeneca (AZN) Gains Approval for Imfinzi in Bladder Cancer Treatment

25,037 Shares in Astrazeneca Plc $AZN Purchased by SBI Okasan Asset Management Co.Ltd. - Stock Observer

Thoroughbred Financial Services LLC Makes New $1.49 Million Investment in AstraZeneca PLC $AZNCF - Stock Observer

CelLBxHealth signs master services agreement with AstraZeneca

AZN Gains FDA Approval for New Bladder Cancer Treatment

Texas Capital Bank Wealth Management Services Inc Acquires Shares of 3,416 Astrazeneca Plc $AZN - Daily Political

What McCormick (MKC)'s Move to Add a Digital and AI Strategist to Its Board Means for Shareholders - Simply Wall St News

AstraZeneca's durvalumab approved in U.S. for NMIBC patients

AstraZeneca, Roche to boost digital pathology uptake in APAC and more briefs

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

Simple Blood Count May Help Predict Flare-Up Risk in Asthma | MDedge

Sun Pharmaceuticals Industries Ltd Futures Share Price & Chart Today | IIFL Capital

Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial results

AstraZeneca (AZN) Receives FDA Approval for Imfinzi in Bladder Cancer Treatment

AstraZeneca (AZN) Gains FDA Approval for Imfinzi in Bladder Cancer Treatment

AstraZeneca (AZN) Secures U.S. Approval for Imfinzi Combination Therapy

AstraZeneca: Oncology and Rare Disease Data at ASCO 2026

Cary Street Partners Financial LLC Makes New Investment in AstraZeneca PLC $AZNCF - Zolmax

Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapy

AZN's Patent Granted in Canada Strengthens Position in Male Infertility Treatment

FDA delays ruling on AstraZeneca drug after negative adcomm vote

William Blair Investment Management LLC Raises Stake in Astrazeneca Plc $AZN - Stock Observer

AstraZeneca falls 7% as Q4 net profit declines 23%; here's a trading strategy for the pharma stock

3,842 Shares in Astrazeneca Plc $AZN Acquired by M3 Wealth Management LLC - Stock Observer

UK Value Opportunities: Serica Energy Among 3 Stocks Priced Below Intrinsic Estimates

Preparing for a time when living to age 120 is commonplace | AfricaPulse.com

Bleakley Financial Group LLC Has $15.34 Million Holdings in Astrazeneca Plc $AZN - Stock Observer

Hantz Financial Services Inc. Buys 39,244 Shares of Astrazeneca Plc $AZN - Stock Observer

Main Street Research LLC Makes New Investment in Astrazeneca Plc $AZN - Stock Observer

GPS Wealth Strategies Group LLC Decreases Stock Holdings in Astrazeneca Plc $AZN - Zolmax

AstraZeneca's Camizestrant: EU Approves Game-Changing Breast Cancer Pill Amid US Concerns, ETPharma

Insider Sell: Mani Sharma Sells Shares of AstraZeneca PLC

FDA Approves AstraZeneca And Daiichi's Datroway For Treating Metastatic Breast Cancer

AstraZeneca (AZN) Gains U.S. Approval for Datroway in Breast Cancer Treatment

AstraZeneca Breast Cancer Drug Recommended for Approval by EU Regulator | Morningstar

AstraZeneca, Daiichi Sankyo's Datroway Gets Approval In US For Treatment Of Breast Cancer

AZN Receives Positive EU Approval Recommendation for Enhertu

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates | Morningstar

AstraZeneca (AZN) Showcases Promising Clinical Data at ASCO Annual Meeting

AstraZeneca's Camizestrant Receives Positive Opinion from EMA

EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug

Vestmark Advisory Solutions Inc. Acquires 93,186 Shares of Astrazeneca Plc $AZN - Stock Observer

Keudell Morrison Wealth Management Buys New Position in Astrazeneca Plc $AZN - Stock Observer

Astrazeneca (NYSE:AZN) Receives "Sell" Rating from Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft Reaffirms Sell Rating for Astrazeneca (NYSE:AZN) - Zolmax

Global Retirement Partners LLC Has $9.85 Million Stock Position in Astrazeneca Plc $AZN - Daily Political

25,822 Shares in AstraZeneca PLC $AZNCF Acquired by Burling Wealth Partners LLC - Stock Observer

How VEPPANU Approval Frames Expectations For AstraZeneca's Camizestrant In ESR1 Disease

Compugen Ltd. (NASDAQ:CGEN) Q1 2026 Earnings Call Transcript

Astrazeneca Plc (NYSE:AZN) Receives $205.33 Average Target Price from Analysts - Zolmax

Harvest Portfolios Group Inc. Sells 39,131 Shares of Astrazeneca Plc $AZN

Astrazeneca Plc $AZN Shares Acquired by Envestnet Portfolio Solutions Inc.

Gabelli Funds LLC Cuts Stock Holdings in Astrazeneca Plc $AZN - Stock Observer

Ultra-high tumor mutation burden breast cancer: genomic profiling and real-world immunotherapy results

AstraZeneca, Roche join forces to boost AI-based cancer pathology across Asia

Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

TEM stock price analysis: Why Tempus AI Stock Up Today?

FTSE 100 index near one-month lows as global sentiment sours

Moderna share price jumps as Oppenheimer upgrades stock

Week ahead: RBA poised to hike?

FTSE 100 Index: London stocks start week sharply lower

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk